Evaluation of the effect of intravenous acetaminophen on opioid consumption and pain control after coronary artery bypass surgery

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170411033365N5

Enrollment

Registered

2024-10-13

Start date

2024-11-20

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart patients undergoing coronary artery bypass surgery.

Interventions

Intervention 1: Intervention group: Intravenous acetaminophen 1 gram. Intervention 2: Control group: 1 gram placebo.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adult cardiac patients undergoing coronary artery bypass surgery

Exclusion criteria

Exclusion criteria: Patients with left ventricular dysfunction with ejection fraction of 35% Severe tricuspid regurgitation Chronic pain conditions that require daily administration or a history of opioid use or dependence prior to surgery Liver disease or liver cirrhosis Preoperative renal failure (creatinine over 2.0, history of hemodialysis) Severe lung disease that requires home oxygen therapy

Design outcomes

Primary

Measure	Time frame
Pain and amount of opioid used, kidney complications, gastrointestinal complications, side effects, time to start from intravenous acetaminophen to oral analgesics. Timepoint: at 4, 6, 8, 12, 16, 20 and 24 hours after coronary artery bypass surgery in intravenous acetaminophen group and placebo group. Method of measurement: Pain with VAS and hospital outcomes with (ICU length of stay, ventilator length of stay and hospital length of stay).	—

Measure

Time frame

Pain and amount of opioid used, kidney complications, gastrointestinal complications, side effects, time to start from intravenous acetaminophen to oral analgesics. Timepoint: at 4, 6, 8, 12, 16, 20 and 24 hours after coronary artery bypass surgery in intravenous acetaminophen group and placebo group. Method of measurement: Pain with VAS and hospital outcomes with (ICU length of stay, ventilator length of stay and hospital length of stay).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Alireza Mahouri

Oroumia University of Medical Sciences

Mahouri.a@umsu.ac.ir+98 44 3346 9931

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026